ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. insider activity: The Interim CEO and COO reported selling 67,500 shares of common stock of ASP Isotopes Inc. on 11/17/2025 at a weighted average price of $7.507 per share. After this transaction, the executive beneficially owns 1,579,693 shares.
The filing explains that the sale was a "sell to cover" transaction made under a Rule 10b5-1 trading plan adopted on June 9, 2025, to cover tax withholding obligations tied to the vesting of restricted stock awards. The shares were sold in multiple trades at prices ranging from $7.215 to $7.85.
ASP Isotopes Inc. (ASPI) reports third-quarter 2025 results reflecting early commercial traction but very heavy losses as it scales its isotope and nuclear fuels platform.
Total revenue reached $4.9 million for the quarter and $7.2 million for the first nine months of 2025, up from $2.95 million a year earlier, driven by both product and new construction services revenue. However, high research and development plus selling, general and administrative costs led to a nine‑month net loss of $96.5 million, compared with $23.2 million in the prior‑year period.
The balance sheet expanded significantly, with cash and cash equivalents of $113.9 million and total assets of $225.9 million as of September 30, 2025, supported by two common stock offerings in June and July 2025 and additional capital raised in October and November. Convertible notes payable at fair value increased to $98.0 million, and total stockholders’ equity rose to $96.6 million.
ASP Isotopes has begun commercial production at two enrichment facilities in South Africa and is preparing initial shipments of enriched C‑12, Si‑28 and C‑14 between late 2025 and the first half of 2026, while also producing Yb‑176 samples. The company is planning additional plants in South Africa, Iceland and the U.S., pursuing a uranium‑235 nuclear fuel initiative, a pending acquisition of Renergen, and a planned spin‑off and U.S. listing of its Quantum Leap Energy (QLE) business, for which a confidential S‑1 has been submitted.
ASP Isotopes Inc. reported that it will host a quarterly business update conference call and webcast on November 21, 2025 at 8:30 a.m. Eastern Time. The company disclosed this plan in a current report and attached the related press release as an exhibit, noting that the call will provide a regular update on its business activities. The press release is furnished for information purposes and is not treated as filed under securities law.
ASP Isotopes Inc. reports that its wholly owned subsidiary Quantum Leap Energy LLC plans to issue approximately $64.3 million of unsecured convertible promissory notes to accredited and non-U.S. investors. The QLE 2025 Notes bear 8.0% annual interest, with principal and interest due on demand by majority noteholders on or after the five-year anniversary of the initial closing. QLE expects to use the net proceeds to build and develop laser enrichment production facilities and for general corporate purposes.
Existing 2024 convertible notes will automatically convert into QLE 2025 Notes at the initial closing, without additional proceeds to QLE or ASPI. The notes convert into equity upon a stock exchange listing, a qualifying equity financing of at least $20 million, certain corporate transactions, or at maturity, generally at a 20% discount or a valuation-based price formula. Holders who do not convert in a qualifying corporate transaction are entitled to unpaid interest plus 1.5× principal. A registration rights agreement will grant demand and piggyback registration rights, including the ability to demand an initial public offering if QLE has not gone public within five years.
ASP Isotopes Inc. (ASPI) announced that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering of QLE’s Class A common stock.
The disclosure was furnished under Item 7.01 (Regulation FD) and, along with the accompanying press release, was issued pursuant to Rule 135. The notice states it does not constitute an offer to sell or a solicitation to buy any securities and will be subject to the registration requirements of the Securities Act.
ASP Isotopes (ASPI) furnished an update on its subsidiary financing. Quantum Leap Energy (QLE), a wholly owned subsidiary, issued an investor presentation and commenced a private placement of QLE convertible promissory notes. QLE entered a definitive purchase agreement for an initial closing of $64.3 million of QLE Notes, led by American Ventures LLC, with ASP Isotopes also making a significant investment. QLE may issue additional notes in subsequent closings to non‑U.S. persons in transactions outside the United States in reliance on Regulation S.
The investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2) are included as exhibits. The information was furnished under Regulation FD and is not deemed filed under the Exchange Act.
ASP Isotopes Inc. (ASPI) reported a corporate update. The company announced that its U.K. subsidiary, Quantum Leap Energy Ltd., has commenced early engagement for regulatory pathways with U.K. nuclear regulators.
The announcement was made via a press release, which is furnished as Exhibit 99.1 and incorporated by reference in this report, other than the fourth and eighth paragraphs of that press release.
ASP Isotopes (ASPI) reported that its subsidiary, Quantum Leap Energy LLC, has completed the purchase of certain assets from One 30 Seven Inc. to advance solutions for processing nuclear waste. The company furnished this update under Item 8.01 and attached a press release as Exhibit 99.1, noting that the ninth paragraph of the release is not incorporated by reference.
ASP Isotopes (ASPI) Form 4: Interim CEO and COO reported a sale of 22,500 shares of common stock on 10/14/2025 at a weighted average price of $13.599. The filing states these were “sell to cover” transactions executed under a Rule 10b5‑1 trading plan adopted on June 9, 2025 to cover tax withholding tied to vesting of restricted stock awards.
Trades occurred across multiple executions at prices ranging from $12.31 to $14.46. Following the transactions, the reporting person beneficially owns 1,647,193 shares directly.
ASP Isotopes Inc. entered into an underwriting agreement to sell 17,167,380 shares of common stock at $11.65 per share. The underwriters have a 30‑day option to purchase up to 2,575,106 additional shares at the same price.
Gross proceeds are expected to be approximately $210.3 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions. The sale is being made under the company’s effective Form S‑3 registration statement with a related prospectus and prospectus supplement. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are acting as underwriters.